Theranostics 2021; 11(15):7308-7321. doi:10.7150/thno.56406 This issue Cite

Research Paper

Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis

Shanshan Gou1, Shuai Wang1, Wenwen Liu1, Guanyu Chen2, Dongyang Zhang1, Jiangfeng Du1, Zhongyi Yan1, Hongfei Wang1, Wenjie Zhai1, Xinghua Sui2, Yahong Wu1, Yuanming Qi1, Yanfeng Gao1,2✉

1. School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.
2. School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China.

Citation:
Gou S, Wang S, Liu W, Chen G, Zhang D, Du J, Yan Z, Wang H, Zhai W, Sui X, Wu Y, Qi Y, Gao Y. Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. Theranostics 2021; 11(15):7308-7321. doi:10.7150/thno.56406. https://www.thno.org/v11p7308.htm
Other styles

File import instruction

Abstract

Graphic abstract

Dendritic cells (DCs) can process the antigens of cancer vaccine and thus stimulate the CD8+ T cells to recognize and kill the tumor cells that express these antigens. However, lack of promising carriers for presenting the antigens to DCs is one of the main barriers to the development of clinically effective cancer vaccines. Another limitation is the risk of inflammatory side effects induced by the adjuvants. It is still unclear how we can develop ideal adjuvant-free DC vaccine carriers without adjuvants.

Methods: A 12-mer peptide carrier (CBP-12) with high affinity for Clec9a expressed on DCs was developed using an in silico rational optimization method. The therapeutic effects of the adjuvant-free vaccine comprising CBP-12 and exogenous or endogenous antigenic peptides were investigated in terms of antigen cross-presentation efficacy, specific cytotoxic T lymphocyte response, and antitumor activity. We also explored the mechanism involved in the antitumor effects of the adjuvant-free CBP-12 vaccine. Finally, we assessed the effects of the CBP-12 conjugated peptide vaccine combined with radiotherapy.

Results: Here, we developed CBP-12 as a vaccine carrier that enhanced the uptake and cross-presentation of the antigens, thus inducing strong CD8+ T cell responses and antitumor effects in both anti-PD-1-responsive (B16-OVA) and -resistant (B16) models, even in adjuvant-free conditions. CBP-12 bound to and activated Clec9a, thereby stimulating Clec9a+ DC to product IL-21, but not IL-12 by activating of Syk. The antitumor effects of the CBP-12 conjugated peptide vaccines could be blocked by an IL-21 neutralizing antibody. We also observed the synergistic antitumor effects of the CBP-12 conjugated peptide vaccine combined with radiotherapy.

Conclusions: CBP-12 could serve as an adjuvant-free peptide vaccine carrier for cancer immunotherapy.

Keywords: Clec9a, dendritic cell, peptide vaccine, cancer immunotherapy, IL-21


Citation styles

APA
Gou, S., Wang, S., Liu, W., Chen, G., Zhang, D., Du, J., Yan, Z., Wang, H., Zhai, W., Sui, X., Wu, Y., Qi, Y., Gao, Y. (2021). Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. Theranostics, 11(15), 7308-7321. https://doi.org/10.7150/thno.56406.

ACS
Gou, S.; Wang, S.; Liu, W.; Chen, G.; Zhang, D.; Du, J.; Yan, Z.; Wang, H.; Zhai, W.; Sui, X.; Wu, Y.; Qi, Y.; Gao, Y. Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. Theranostics 2021, 11 (15), 7308-7321. DOI: 10.7150/thno.56406.

NLM
Gou S, Wang S, Liu W, Chen G, Zhang D, Du J, Yan Z, Wang H, Zhai W, Sui X, Wu Y, Qi Y, Gao Y. Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. Theranostics 2021; 11(15):7308-7321. doi:10.7150/thno.56406. https://www.thno.org/v11p7308.htm

CSE
Gou S, Wang S, Liu W, Chen G, Zhang D, Du J, Yan Z, Wang H, Zhai W, Sui X, Wu Y, Qi Y, Gao Y. 2021. Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. Theranostics. 11(15):7308-7321.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image